Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytoDyn Inc.
Report date March 31, 2022 · Filed June 08, 2022
Section 16 reporting ended · disclosed 2022-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 716,746 |
Ending reported balance
After 2022-04-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-31 · Grant · Acquired 12,950 · Balance 699,000 F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Row 2 · 2022-04-15 · Grant · Acquired 17,746 · Balance 716,746 F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2022 Filed Jun 8, 2022 20:06 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 17,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069300 · tm2217755-2_4seq1.xml · nonDerivative · entry 2 Recknor Chris P · CIK 0001850917 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,746 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| March 31, 2022 Filed Jun 8, 2022 20:06 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 12,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069300 · tm2217755-2_4seq1.xml · nonDerivative · entry 1 Recknor Chris P · CIK 0001850917 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,000 F1 · shares: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:17 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 1,450,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000899243-21-032385 · doc4.xml · derivative · entry 2 Recknor Chris P · CIK 0001850917 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450,000 Underlying: Common stock · 1,450,000 shares Expires 2031-08-06 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on August 6, 2022. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:17 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 19,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032385 · doc4.xml · nonDerivative · entry 1 Recknor Chris P · CIK 0001850917 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,050 F1 · shares: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. F1 · price: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.